doi:10.16597/j.cnki.issn.1002-154x.2023.03.008
法尼醇 X 受体治疗非酒精性脂肪性肝病研究进展
曾思铭 张晨晨 卓越∗
(佳木斯大学附属第一医院,黑龙江 佳木斯 154000)
Research Advances in the Treatment of Nonalcoholic Fatty Liver Disease by Farnixol X Receptors
Zeng Siming Zhang Chenchen Zhuo Yue ∗
(The First Affiliated Hospital of Jiamusi University, Heilongjiang Jiamusi 154000)
摘要:
非酒精性脂肪性肝病(NAFLD)是代谢综合征的肝脏表现,其主要表现为肝脂肪变性。 近年来法尼醇 X 受体 (FXR)被发现参与胆汁酸、糖脂代谢,抑制炎症参与碳水化合物的代谢,被认为是一类有治疗前景的药物治疗靶点。
关键词：非酒精性脂肪性肝病 法尼醇 X 受体 胆汁酸 奥贝胆酸；
Abstract：
Non-alcoholic fatty liver disease (NAFLD) is a manifestation of metabolic syndrome, which mainly shows as hepatic steatosis. Recent years, Fanidol X receptor (FXR) has been found to be involved in the metabolism of bile acid, glycolipid and inhibition of inflammation involved in carbohydrate, which is considered as a promising therapeutic target of drug therapy.
Keywords：non-alcoholic fatty liver disease; Farnidol; X receptors; bile acids; obeticholic acid;